Roberto Sauma - Genomma Lab Independent Director

LABB Stock  MXN 16.30  0.50  3.16%   

Director

Mr. Roberto Simon Sauma serves as Independent Director of Genomma Lab Internacional, S.A.B. de C.V. since April 15, 2015. He served as Administrative Director and Director General at Hospital Angeles of Pedregal. He also served as Executive Director for Corporationrationrate Business Group Angeles, SA de C.V. from 1998 to 1999 and Executive Director at Grupo Empresarial ngeles, S.A. de C.V. from 1999 to 2000. He also serves as CEO of Grupo ngeles Servicios de Salud, S.A. de C.V. since 2000. He holds a Master degree in Medicine from the Universidad Nacional Autonoma de Mexico. since 2015.
Tenure 9 years
Phone52 55 5081 0000
Webhttps://www.genommalab.com

Genomma Lab Management Efficiency

The company has return on total asset (ROA) of 0.0921 % which means that it generated a profit of $0.0921 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1264 %, meaning that it generated $0.1264 on every $100 dollars invested by stockholders. Genomma Lab's management efficiency ratios could be used to measure how well Genomma Lab manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 3.83 B in total debt with debt to equity ratio (D/E) of 0.61, which is about average as compared to similar companies. Genomma Lab Internacional has a current ratio of 1.72, which is within standard range for the sector. Debt can assist Genomma Lab until it has trouble settling it off, either with new capital or with free cash flow. So, Genomma Lab's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genomma Lab Internacional sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genomma to invest in growth at high rates of return. When we think about Genomma Lab's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

James CrownJPMorgan Chase Co
65
Linda BammannJPMorgan Chase Co
63
Paul WalshHSBC Holdings plc
60
Peter BonfieldTaiwan Semiconductor Manufactur
74
Diana TaylorCitigroup
63
Stan ShihTaiwan Semiconductor Manufactur
N/A
Lew JacobsCitigroup
47
Janis LomaxHSBC Holdings plc
69
Michael NealJPMorgan Chase Co
66
Ernesto LeonCitigroup
66
Thomas EngibousTaiwan Semiconductor Manufactur
61
Henri CastriesHSBC Holdings plc
64
Franz HumerCitigroup
71
Arnold DonaldBank of America
64
Michael WhiteBank of America
67
Jonathan EvansHSBC Holdings plc
59
Meiling ChenTaiwan Semiconductor Manufactur
N/A
Thomas MayBank of America
72
Pauline MohrHSBC Holdings plc
58
Gary ReinerCitigroup
63
Renee JamesCitigroup
53
Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico, the United States, and Latin America. Genomma Lab Internacional, S.A.B. de C.V. was founded in 1996 and is based in Mexico City, Mexico. GENOMMA LAB operates under Drug ManufacturersSpecialty Generic classification in Mexico and is traded on Mexico Stock Exchange. It employs 1451 people. Genomma Lab Internacional (LABB) is traded on Mexican Exchange in Mexico and employs 2,297 people.

Management Performance

Genomma Lab Internacional Leadership Team

Elected by the shareholders, the Genomma Lab's board of directors comprises two types of representatives: Genomma Lab inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomma. The board's role is to monitor Genomma Lab's management team and ensure that shareholders' interests are well served. Genomma Lab's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomma Lab's outside directors are responsible for providing unbiased perspectives on the board's policies.
Maximo Juda, CEO, COO and Executive Vice-Pres
Scott Emerson, Independent Director
Stefano Curti, Global President of Brands
Cesar Lopez, Vice President of Global Marketing
Efran Crdova, Deputy Sec
Ramon Sastre, Executive Vice President of Institutional Relations
Carlos Alonso, Independent Director
Marianne Velasco, Global HR
Marco Munoz, Non-Member Secretary of the Board of Directors
Jorge Munoz, Independent Director
Ignacio Rodriguez, Independent Director
Alejandro Patino, Executive Vice President of Human Capital and Commercial Expansion
L Porres, Legal Officer
Leandro Gold, Independent Director
Jose Fernandez, Independent Director
Rodrigo Aspra, Chairman of the Board, Independent Director
Claudia Vettoretti, Vice-President of Marketing
Renata Aspra, COO and Executive Vice-Pres
Juan Gavito, Independent Director
Antonio Galland, Executive Vice President, Chief Financial and Chief Administrative Officer
Luis MacKissack, Director
Arturo Perez, Director
Hector Gonzalez, Independent Director
Burkhard Wittek, Director
Alejandro Patio, Media, Relations
Marco Sparvieri, Executive Vice-President of Global Sales
Javier Castilla, Independent Director
Engineer Galland, Exec CFO
Sabrina Aspra, Director of International Operations, Director
Mximo Juda, Advisor
Daniel Neria, Head Relations
Juan Alonso, Independent Director
Santiago Pelaez, Vice President of Industrial and Research and Development
Jorge Valderrama, Chief Executive Officer
Juan Sparvieri, Chief Operating Officer, Vice President
Roberto Sauma, Independent Director
Leticia Herrera, Global Director of Human Resources (Genomma Experience)

Genomma Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genomma Lab a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Genomma Lab Internacional. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Genomma Stock analysis

When running Genomma Lab's price analysis, check to measure Genomma Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomma Lab is operating at the current time. Most of Genomma Lab's value examination focuses on studying past and present price action to predict the probability of Genomma Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomma Lab's price. Additionally, you may evaluate how the addition of Genomma Lab to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Please note, there is a significant difference between Genomma Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genomma Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genomma Lab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.